<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21637" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fatal Familial Insomnia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khan</surname>
            <given-names>Zalan</given-names>
          </name>
          <aff>University of Missouri Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sankari</surname>
            <given-names>Abdulghani</given-names>
          </name>
          <aff>Wayne State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bollu</surname>
            <given-names>Pradeep C.</given-names>
          </name>
          <aff>University of Missouri</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zalan Khan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdulghani Sankari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pradeep Bollu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21637.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Fatal familial insomnia is a very rare and invariably fatal autosomal dominant neurodegenerative prion disease caused by a mutation of the prion protein (<italic toggle="yes">PRNP</italic>) gene. Hallmarks of the disease include aggressively progressive insomnia; subsequent autonomic disturbances, including tachycardia, hyperhidrosis, and hypertension; cognitive disturbances, including deficits in short-term memory and attention; balance problems; and endocrine dysfunction. The disease is currently incurable and has an average duration of 18 months, ultimately leading to death.&#x000a0;A detailed history and neurological examination are of paramount importance as fatal familial insomnia is primarily a clinical diagnosis.&#x000a0;Treatment is centered mainly on symptomatic relief and palliative care, as there is no cure for FFI.&#x000a0;This activity for healthcare professionals aims to enhance learners' competence in selecting appropriate diagnostic tests, managing&#x000a0;fatal familial insomnia, and fostering effective interprofessional teamwork to improve outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify characteristic symptoms of fatal familial insomnia, distinguishing them from other sleep disorders.</p></list-item><list-item><p>Implement evidence-based interventions for fatal familial insomnia management, addressing both symptomatic relief and supportive care.</p></list-item><list-item><p>Apply appropriate palliative measures to alleviate suffering and enhance quality of life.</p></list-item><list-item><p>Implement interprofessional team strategies for enhancing care coordination to manage fatal familial insomnia and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21637&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21637">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21637.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Fatal familial insomnia (FFI) is a very rare and fatal inherited neurodegenerative prion disease. The mode of inheritance of this disease is autosomal dominant and involves a mutation of the prion protein (<italic toggle="yes">PRNP</italic>) gene, leading to atrophy in the thalamic nucleus.<xref ref-type="bibr" rid="article-21637.r1">[1]</xref><xref ref-type="bibr" rid="article-21637.r2">[2]</xref> Aggressively progressive insomnia, with subsequent autonomic (eg, tachycardia, hyperhidrosis, hypertension), cognitive (eg, short-term memory and attentional deficits), motor system (eg, balance problems), and endocrine dysfunction are hallmarks of the disease. The disease is currently&#x000a0;incurable and has a mean course of 18 months, ultimately leading to death.</p>
        <p>The earliest description of the disease dates back to 1765, with a report of an Italian man with symptoms suggestive of FFI. The disease was formally identified and clinically described in 1986 by Lugaresi E et al, followed by subsequent studies further describing its pathophysiology, etiology, and clinical course.<xref ref-type="bibr" rid="article-21637.r3">[3]</xref><xref ref-type="bibr" rid="article-21637.r4">[4]</xref>&#x000a0;A detailed history and neurological examination are of paramount importance as fatal familial insomnia is primarily a clinical diagnosis.&#x000a0;Treatment is centered mainly on symptomatic relief and palliative care, as there is no cure for FFI.&#x000a0;</p>
      </sec>
      <sec id="article-21637.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>FFI is part of a family of&#x000a0;genetic human prion diseases, including familial Creutzfeldt-Jakob disease, prion protein amyloidosis, Gerstmann-Straussler-Scheinker syndrome, and Huntington disease-like 1.<xref ref-type="bibr" rid="article-21637.r2">[2]</xref>&#x000a0;The cause of FFI has been identified as an autosomal dominant mutation at the codon 178 of the <italic toggle="yes">PRNP</italic> gene, located&#x000a0;on the short (p) arm of chromosome 20 at position p13 (20p13), responsible for making the prion protein PrPC.&#x000a0;Approximately 10% to 15% of all cases diagnosed with prion disease are inherited due to autosomal dominant mutations in the <italic toggle="yes">PRPN</italic> gene.&#x000a0;Specifically, FFI is genetically due to a mutation called D178N,&#x000a0;associated&#x000a0;with the M129 genotype in the <italic toggle="yes">pPrPC</italic> gene. Although it is unknown when the disease occurs, evidence suggests that the&#x000a0;onset of the disease depends on the critical amount of prion protein conversion to the faulty prion protein.<xref ref-type="bibr" rid="article-21637.r4">[4]</xref><xref ref-type="bibr" rid="article-21637.r5">[5]</xref><xref ref-type="bibr" rid="article-21637.r6">[6]</xref></p>
      </sec>
      <sec id="article-21637.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Worldwide, hundreds of cases of FFI have been documented, predominantly in Europe and Asia, with a notable increase in recent years, particularly in China.<xref ref-type="bibr" rid="article-21637.r7">[7]</xref>&#x000a0;A total of 131 FFI patients were identified and reported, including 57 women and 72 men. The average disease onset age was 47.5 years, ranging from 17 to 76 years. In the same report, 106 patients passed away, and the disease duration averaged 13.2 months, with a range of 2 to 48 months.<xref ref-type="bibr" rid="article-21637.r8">[8]</xref>&#x000a0;The connection between the variations in characteristics across regions and genetic makeup is a subject of scientific interest. A small-scale study suggested that a particular genetic difference at codon 129 of <italic toggle="yes">PRNP</italic> might be linked to the features of FFI disease. Among Asians, there is an occurrence of symptoms like movements, sleep breathing difficulties, and laryngeal stridor. Additionally, another separate cluster displayed hypertension, excessive sweating, and weight loss. On the other hand, Asians have rates of diplopia (ie, double vision) and myoclonus compared to other ethnicities.<xref ref-type="bibr" rid="article-21637.r8">[8]</xref>&#x000a0;Overall, genetic prion diseases are very rare. Annually, 1 to 1.5 new cases of genetic and nongenetic prion diseases per 1 million people.<xref ref-type="bibr" rid="article-21637.r9">[9]</xref>&#x000a0;Hereditary&#x000a0;forms of prion disease constitute approximately 10% of the total cases of prion diseases.<xref ref-type="bibr" rid="article-21637.r1">[1]</xref></p>
      </sec>
      <sec id="article-21637.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>FFI neuropathological changes&#x000a0;include&#x000a0;neuronal loss and gliosis, particularly in the thalamus, which is responsible for various sensory and motor functions and sleep regulation.<xref ref-type="bibr" rid="article-21637.r10">[10]</xref>&#x000a0;Hence, these neuropathological changes contribute to the clinical manifestations of FFI, including severe sleep disturbances and autonomic dysfunction. The spread of pathological changes to different brain regions explains the diverse clinical features observed in individuals with FFI.</p>
        <p>Parietal, temporal, and frontal lobes have shown higher involvement degrees than the occipital lobe. Furthermore, the involvement of the brain cortex in almost all cases,&#x000a0;with&#x000a0;the degree of&#x000a0;spongiosis and astrogliosis, is positively correlated to the duration of the disease. However, the prion protein&#x02019;s deposition pattern favors the brainstem and thalamus earlier in the disease,&#x000a0;with the thalamus being&#x000a0;most affected by the&#x000a0;degenerative changes. The reason for this involvement pattern is poorly understood but can explain the variety of symptoms seen in the disease.<xref ref-type="bibr" rid="article-21637.r4">[4]</xref><xref ref-type="bibr" rid="article-21637.r6">[6]</xref><xref ref-type="bibr" rid="article-21637.r9">[9]</xref></p>
      </sec>
      <sec id="article-21637.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>A Western blot and immunocytochemistry test on human brains showed a disconnection between the amount and location of prion protein deposits, the protease-resistant form, and the severity of the histopathological changes. In a study examining the patient's cerebellar cortex, prion protein deposits were heavily concentrated in the molecular layer and exhibited a unique patchy and strip-like pattern perpendicular to the surface.<xref ref-type="bibr" rid="article-21637.r11">[11]</xref>&#x000a0;In another patient from the same study, a single neuron in the inferior olivary nuclei contained abundant protease-resistant prion protein deposits within its vacuoles, which resembled the changes seen in brainstem neurons in bovine spongiform encephalopathy.</p>
      </sec>
      <sec id="article-21637.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with FFI most commonly become symptomatic between the ages of 20 and 61 years, with an average age of 50 years. FFI usually manifests with heterogeneous clinical phenotypes&#x000a0;and pronounced neuronal loss and gliosis, particularly in the thalamus.<xref ref-type="bibr" rid="article-21637.r12">[12]</xref>&#x000a0;A detailed history and neurological examination are important&#x000a0;as FFI is primarily a clinical diagnosis. When interviewing and examining a patient with possible FFI, the following features should be considered:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Sleep disturbance:</bold> Patients can initially present with insomnia (ie, delayed sleep onset latency and decreased total sleep time), which increases in severity as the disease progresses. However, vivid dreaming is common during the limited amount of sleep time. In addition, disruption of normal sleep architecture, increased frequency of periodic leg movements, and central sleep apnea were reported in 40% to 60% of patients.<xref ref-type="bibr" rid="article-21637.r12">[12]</xref>&#x000a0;As the FFI disease progresses, it can disrupt the circadian sleep-wake cycle, leading to a confused state during wakefulness (ie, dreamlike status).<xref ref-type="bibr" rid="article-21637.r13">[13]</xref><xref ref-type="bibr" rid="article-21637.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Autonomic dysfunction:</bold> The patient may present with varying degrees of autonomic dysfunction, including high blood pressure, episodes of tachypnea, increased lacrimation and sweating, constipation, sexual dysfunction, and variabilities in body temperature.<xref ref-type="bibr" rid="article-21637.r15">[15]</xref><xref ref-type="bibr" rid="article-21637.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Neurological impairments:</bold>&#x000a0;Due to the joint involvement of the brainstem, multiple cranial nerves can be affected. Patients can present with double vision early in the disease, swallowing difficulties, and gaze abnormalities.&#x000a0;In addition, the onset of extrapyramidal signs and hallucinations occur after a median duration of 12 weeks, after which loss of temporal and spatial orientation becomes evident. Subsequently, dysarthria, ataxia, myoclonus, movement disorders, gait difficulty, and pyramidal signs emerge later in the disease course.<xref ref-type="bibr" rid="article-21637.r16">[16]</xref>&#x000a0;Gait dysfunction in FFI can be affected by the disease's duration, which is also determined by the genotype. The progression of gait dysfunction during the disease may reflect the spread of neuronal degeneration from the thalamus to other brain regions involved in gait control.<xref ref-type="bibr" rid="article-21637.r17">[17]</xref> The bulbar and vegetative symptoms and signs become more apparent much later in the disease course, whereas hallucinations were not observed in patients until the advanced stages of the disease. The cortical involvement can manifest as slowing thought processing, attentional disturbances, and short-term memory loss. As the disease progresses, a delirium- condition develops.<xref ref-type="bibr" rid="article-21637.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Mental health disease:</bold> Behavioral and intellectual capacity remains&#x000a0;largely&#x000a0;intact even in the late stages. Mood changes are common as patients may become depressed or apathetic as insomnia worsens. Behavioral and intellectual capacity tends to remain&#x000a0;largely&#x000a0;intact even in the late stages of the disease.<xref ref-type="bibr" rid="article-21637.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Systemic and endocrine changes:</bold>&#x000a0;Progressive frailty and weight loss are seen in most patients.<xref ref-type="bibr" rid="article-21637.r11">[11]</xref>&#x000a0;In addition, endocrine dysfunction has been reported as decreased corticotropin (ACTH) secretion and increased cortisol secretion. Additionally, FFI can cause a loss of the normal diurnal variations in growth hormone levels, melatonin, and prolactin.<xref ref-type="bibr" rid="article-21637.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Diagnostic Clinical Features</bold>
</p>
        <p>In 2022, an international group established diagnostic clinical criteria to help differentiate FFI from other differential diagnoses with similar presenting symptoms and identify the disease at earlier stages. The duration of the following core symptoms is typically &#x0003c;2 years:</p>
        <list list-type="bullet">
          <list-item>
            <p>Organic sleep disturbances, including intractable insomnia, agrypnia excitata with or without laryngeal stridor, sleep apnea, or involuntary movements (eg,&#x000a0;hypnic jerks, restless sleep with frequent body position changes)</p>
          </list-item>
          <list-item>
            <p>Neurologic and mental health impairment, including rapidly progressive dementia, ataxia, myoclonus, hallucination, delusion, or personality changes (eg,&#x000a0;depression, anxiety, apathy, and confusion)</p>
          </list-item>
          <list-item>
            <p>Progressive autonomic and systemic abnormalities, including hypertension, tachycardia, irregular breathing, hyperthermia, sweating, or weight loss &#x0003e;10 kg during the last 6 months&#x000a0;<xref ref-type="bibr" rid="article-21637.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>In addition to the core clinical features, the following features support a FFI diagnosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Family history of organic insomnia symptoms</p>
          </list-item>
          <list-item>
            <p>Probable organic insomnia (eg, loss of circadian rhythm, sleep fragmentation, reduction of total sleep time, or sleep&#x02013;wake cycle disruption) with or without involuntary movements on video polysomnography&#x000a0;<xref ref-type="bibr" rid="article-21637.r20">[20]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21637.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>FFI is diagnosed clinically; however, various diagnostic studies are typically performed to support the diagnosis and exclude other conditions.<xref ref-type="bibr" rid="article-21637.r20">[20]</xref></p>
        <p>
<bold>Diagnostic Studies&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The initial workup should include a complete blood count (CBC), erythrocyte sedimentation rate (ESR), serum chemistry, liver function tests (LFT), ammonia levels, and blood cultures for suspected bacterial infections.</p>
          </list-item>
          <list-item>
            <p>Investigating reversible causes of cognitive decline should include thyroid function tests (TFT), vitamin B-12, and folate levels, along with testing for neurosyphilis and human immunodeficiency virus (HIV) testing.</p>
          </list-item>
          <list-item>
            <p>Polysomnography (PSG)&#x000a0;can show a reduction in total sleep time and a dysfunctional transition between sleep stages. Specifically, PSG shows reduced REM sleep, reduced sleep efficiency, and slow wave sleep.<xref ref-type="bibr" rid="article-21637.r12">[12]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Electroencephalogram (EEG) Periodic sharp-wave complexes (PSWC) can suggest prion disease but are seen in only a small percentage of patients with genetic forms of prion disease. Pathogenic variants with pronounced spongiform degeneration and CJD-like clinical presentation are more likely to have an abnormal EEG. Although non-specific, patients with FFI show generalized slowing without periodic sharp-wave complexes.<xref ref-type="bibr" rid="article-21637.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Cerebrospinal Fluid (CSF)<bold>&#x000a0;</bold>studies for biomarkers (eg, 14-3-3 protein) are non-specific and may be seen in various diseases, causing neuronal death.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Imaging Studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Computed tomography (CT) and magnetic resonance imaging (MRI) have limited value in diagnosing FFI but may help rule out other neurological pathologies.</p>
          </list-item>
          <list-item>
            <p>Reduced thalamic diffusion may be present on diffusion MRI due to gliosis. Atrophic changes may become evident as the disease progresses.</p>
          </list-item>
          <list-item>
            <p>Fluorodeoxyglucose positron emission tomography (FDG-PET) examinations can potentially aid in diagnosing FFI. PET imaging can reveal hypometabolism in the thalamic and cingulate regions with a tendency to spare the occipital lobe.<xref ref-type="bibr" rid="article-21637.r21">[21]</xref></p>
          </list-item>
        </list>
        <p><bold>Molecular Genetic Testing:&#x000a0;</bold>Suspected patients should undergo genetic testing for targeted analysis of the pathogenic variant of <italic toggle="yes">PRNP</italic> or full gene sequencing.</p>
        <p><bold>Histopathological Testing:&#x000a0;</bold>Brain biopsies, although nondiagnostic for FFI, may be considered to rule out other neurological diseases.</p>
        <p>
<bold>Diagnostic A</bold>
<bold>pproach</bold>
</p>
        <p>Polysomnography and genetic testing are recommended following comprehensive genetic counseling. Specifically, conducting a targeted screening for the D178N mutation of the&#x000a0;<italic toggle="yes">PRNP</italic>&#x000a0;gene can aid in diagnosing FFI at an early stage.<xref ref-type="bibr" rid="article-21637.r2">[2]</xref>While clinical diagnostics can provide valuable information, genetic testing, and counseling can help confirm a diagnosis and identify potential risks for family members. Additionally, targeted screening for specific genetic mutations, such as the D178N mutation of&#x000a0;<italic toggle="yes">PRNP</italic>, can be instrumental in establishing an early diagnosis and developing effective treatment plans.<xref ref-type="bibr" rid="article-21637.r12">[12]</xref></p>
        <p>Using the 2022 international group diagnostic criteria, the likelihood of FFI can be determined. This diagnostic approach consists of the core clinical and supportive features and the following diagnostic study findings, and exclusionary factors:<xref ref-type="bibr" rid="article-21637.r20">[20]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Exclusionary features
<list list-type="bullet"><list-item><p>Periodic sharp wave complex on EEG</p></list-item><list-item><p>Hyperintense signal in the caudate nucleus and putamen or &#x02265;2 cortical regions on&#x000a0;imaging or MRI sequencing</p></list-item><list-item><p>Pattern of deficits explained by differential diagnoses</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Diagnostic studies: positive molecular genetic testing for&#x000a0;<italic toggle="yes">PRNP</italic> mutation</p>
          </list-item>
          <list-item>
            <p>Probability of FFI diagnosis based on diagnostic criteria
<list list-type="bullet"><list-item><p>Possible FFI: 2 out of 3 core clinical features without any exclusion features present</p></list-item><list-item><p>Probable FFI: 2 out of 3 core clinical features, &#x02265;&#x02009;1 supportive feature without any exclusion features present</p></list-item><list-item><p>Definite FFI: 2 out of 3 core clinical features and positive diagnostic studies</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21637.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment is largely centered on symptomatic relief and palliative care, as there is no cure for FFI. Different treatment modalities mentioned in the literature are as follows.</p>
        <list list-type="bullet">
          <list-item>
            <p>Discontinuation of medications that may exacerbate confusion, memory, and insomnia is essential.</p>
          </list-item>
          <list-item>
            <p>FFI patients show an inadequate response to sedatives. Tinuper P et al described a lack of effect of barbiturates or benzodiazepines on EEG in FFI patients.<xref ref-type="bibr" rid="article-21637.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Problems with swallowing may warrant the placement of a feeding tube.</p>
          </list-item>
          <list-item>
            <p>A case report investigated gamma-hydroxybutyrate (GHB) and found its administration to induce slow-wave sleep (SWS) in a patient with FFI.<xref ref-type="bibr" rid="article-21637.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Several treatments using compounds such as pentosane polysulfate, quinacrine, and amphotericin B have been studied with inconclusive results.<xref ref-type="bibr" rid="article-21637.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>A clinical trial is currently being conducted in Italy to prevent the onset of prion disease in individuals who are carriers of the <italic toggle="yes">PRNP</italic> D178N/M129 mutation. The study involves administering the antibiotic doxycycline 100 mg orally daily for 10 years to 10 carriers and comparing the results with a control group of 15 noncarriers from the same family. The trial is ongoing, and the outcomes are yet to be determined.<xref ref-type="bibr" rid="article-21637.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Immunotherapy has reported promising results in vitro and in vivo in animal studies and clinical trials. The 3 main&#x000a0;types&#x000a0;of immunotherapy research focus on antibody vaccines, dendritic cell vaccines, and adoptive transfer of physiological prion protein-specific CD4(+) T-lymphocytes. Antibody vaccines aim to target unique epitopes only displayed on the misfolded form of prion protein (PrP(Sc)).<xref ref-type="bibr" rid="article-21637.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Psychosocial therapy is essential for both the patient and the family. Hospice care can also be beneficial.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21637.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>When evaluating patients with FFI, consideration of other prion diseases due to overlap in symptomatology is essential,<xref ref-type="bibr" rid="article-21637.r6">[6]</xref><xref ref-type="bibr" rid="article-21637.r26">[26]</xref> including the following:<xref ref-type="bibr" rid="article-21637.r6">[6]</xref><xref ref-type="bibr" rid="article-21637.r26">[26]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Sporadic Creutzfeldt-Jakob disease (sCJD) and familial Creutzfeldt-Jakob disease (fCJD) are clinically and pathologically similar, with sCJD being more aggressive&#x000a0;with a later onset. Both primarily present with memory problems and confusion, followed by myoclonus and ataxia. Spongiform degeneration and astrogliosis are more profuse and widespread compared to FFI.<xref ref-type="bibr" rid="article-21637.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Sporadic familial insomnia (sFI)&#x000a0;is well-defined genetic, clinical, and histopathological features that mimic FFI but without the presence of a genetic mutation. Like other neurodegenerative diseases, sFI lacks a precise animal model and effective therapeutic intervention. Developing a precise disease model is crucial to understanding the pathogenic mechanism.<xref ref-type="bibr" rid="article-21637.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Gerstmann-Straussler-Scheinker syndrome (GSS) typically manifests with impairments in cerebellar functioning, with little to no disturbance in sleep. Cognitive dysfunction is generally minimal and, if present, is more likely to be observed in the later stages of the disorder. The mode of inheritance for this condition is autosomal dominant, and it displays high penetrance, which can be attributed to a range of point mutations and insertion mutations involving octapeptide repeats.<xref ref-type="bibr" rid="article-21637.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Variably protease-sensitive prionopathy can present with varying degrees of aphasia and behavioral symptoms and is best diagnosed with histopathological examination.</p>
          </list-item>
          <list-item>
            <p>Lithium toxicity</p>
          </list-item>
          <list-item>
            <p>Familial myoclonic dementia</p>
          </list-item>
          <list-item>
            <p>Diffuse Lewy body disease</p>
          </list-item>
          <list-item>
            <p>Chronic meningitis</p>
          </list-item>
          <list-item>
            <p>Dementia as a paraneoplastic syndrome</p>
          </list-item>
          <list-item>
            <p>Dementia in motor neuron disease</p>
          </list-item>
          <list-item>
            <p>Nonherpes viral encephalitis</p>
          </list-item>
          <list-item>
            <p>Hashimoto encephalopathy (or steroid-responsive encephalopathy associated with autoimmune thyroiditis [SREAT])</p>
          </list-item>
          <list-item>
            <p>Limbic encephalitis (and other paraneoplastic syndromes)<xref ref-type="bibr" rid="article-21637.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>Furthermore, ruling out other causes of dementia, which may be reversible, is necessary. Some of these include, but are not limited to, herpes encephalitis, paraneoplastic syndromes including limbic encephalitis, Hashimoto encephalitis, lithium poisoning, chronic meningitis, HIV encephalopathy, and hydrocephalus.<xref ref-type="bibr" rid="article-21637.r30">[30]</xref><xref ref-type="bibr" rid="article-21637.r31">[31]</xref>&#x000a0;Neurodegenerative diseases, including Alzheimer's disease, Pick disease, corticobasal degeneration, multiple system atrophy, frontotemporal dementia, and familial myoclonic dementia, irrespective of their slow progression, should be considered during evaluation.<xref ref-type="bibr" rid="article-21637.r32">[32]</xref></p>
      </sec>
      <sec id="article-21637.s11" sec-type="Staging">
        <title>Staging</title>
        <p>FFI has been described as having 4 stages:</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 1: The first stage of the disease is identified by the subacute onset of insomnia, which worsens over a few months and causes psychiatric symptoms such as phobia, paranoia, and panic attacks. During this time, patients may report lucid dreaming.</p>
          </list-item>
          <list-item>
            <p>Stage 2: In the next 5-month period, psychiatric symptoms worsen along with worsening insomnia, and patients experience hallucinations. Autonomic dysfunction in the form of sympathetic hyperactivity is seen.</p>
          </list-item>
          <list-item>
            <p>Stage 3: This short stage of around 3 months is typically dominated by total insomnia and complete sleep-wake cycle disruptions.</p>
          </list-item>
          <list-item>
            <p>Stage 4: The final stage of the disease can last for 6 months or more and is defined by rapid cognitive decline and dementia. Patients experience an inability to voluntarily move or speak, which&#x000a0;is followed by coma and eventual death.<xref ref-type="bibr" rid="article-21637.r33">[33]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21637.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The disease course can last from 7 to 36 months, with an average duration of 18 months leading to eventual death. Patients with homozygous (Met-Met) mutation have a shorter mean survival time than heterozygous (Met-Val) patients.<xref ref-type="bibr" rid="article-21637.r34">[34]</xref><xref ref-type="bibr" rid="article-21637.r35">[35]</xref></p>
      </sec>
      <sec id="article-21637.s13" sec-type="Complications">
        <title>Complications</title>
        <p>FFI is universally fatal.&#x000a0;Various autonomic, cognitive, motor, and endocrine complications. Refer to the History and Physical&#x000a0;section for more information on complications of FFI.</p>
      </sec>
      <sec id="article-21637.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients and families should be thoroughly educated about the fatal course of FFI. They should also be informed that there are currently limited treatment options, but studies are ongoing. Genetic counseling should be offered to family members as well.</p>
      </sec>
      <sec id="article-21637.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>FFI is a rare, hereditary prion disease characterized by relentless insomnia leading to severe neurodegeneration. Clinicians must recognize its unique symptoms, including sleep disturbances and autonomic dysfunction. Early identification through genetic testing is crucial. Management involves symptomatic relief, palliative care, and an&#x000a0;interprofessional approach. The prognosis is poor, with death typically occurring within a year.&#x000a0;</p>
        <p>FFI&#x000a0;is best managed by an interprofessional team, including sleep specialists, neurologists, psychiatrists and psychologists, social workers, palliative nurses, and hospice care. Hospice should be involved early in the care.&#x000a0;Psychosocial counseling&#x000a0;for&#x000a0;family members is&#x000a0;necessary as well.&#x000a0;Effective communication is essential in supporting patients and families through the complex challenges of FFI, emphasizing compassionate end-of-life care and addressing psychological and social aspects alongside medical considerations.</p>
      </sec>
      <sec id="article-21637.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21637&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21637">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/fatal-familial-insomnia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21637">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21637/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21637">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21637.s17">
        <title>References</title>
        <ref id="article-21637.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nafe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arendt</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Hattingen</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Human prion diseases and the prion protein - what is the current state of knowledge?</article-title>
            <source>Transl Neurosci</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>20220315</fpage>
            <pub-id pub-id-type="pmid">37854584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bagyinszky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giau</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Youn</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>SSA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Characterization of mutations in <italic>PRNP</italic> (prion) gene and their possible roles in neurodegenerative diseases.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2018</year>
            <volume>14</volume>
            <fpage>2067</fpage>
            <page-range>2067-2085</page-range>
            <pub-id pub-id-type="pmid">30147320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Medori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tritschler</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>LeBlanc</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tinuper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia: a second kindred with mutation of prion protein gene at codon 178.</article-title>
            <source>Neurology</source>
            <year>1992</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>3 Pt 1</issue>
            <fpage>669</fpage>
            <page-range>669-70</page-range>
            <pub-id pub-id-type="pmid">1347910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schenkein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Self management of fatal familial insomnia. Part 1: what is FFI?</article-title>
            <source>MedGenMed</source>
            <year>2006</year>
            <month>Sep</month>
            <day>14</day>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>65</fpage>
            <pub-id pub-id-type="pmid">17406188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Avoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tinuper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Plazzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gallassi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Portaluppi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Julien</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vital</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delisle</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene.</article-title>
            <source>Brain Pathol</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>515</fpage>
            <page-range>515-20</page-range>
            <pub-id pub-id-type="pmid">9669701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Zerr</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Genetic Prion Disease</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2003</year>
            <month>3</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">20301407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>XP</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological characteristics of human prion diseases.</article-title>
            <source>Infect Dis Poverty</source>
            <year>2016</year>
            <month>Jun</month>
            <day>02</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <pub-id pub-id-type="pmid">27251305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>TX</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical profile of fatal familial insomnia: phenotypic variation in 129 polymorphisms and geographical regions.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>93</volume>
            <issue>3</issue>
            <fpage>291</fpage>
            <page-range>291-297</page-range>
            <pub-id pub-id-type="pmid">34667102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tinuper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Medori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zucconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baruzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The thalamus participates in the regulation of the sleep-waking cycle. A clinico-pathological study in fatal familial thalamic degeneration.</article-title>
            <source>Electroencephalogr Clin Neurophysiol</source>
            <year>1989</year>
            <month>Aug</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-23</page-range>
            <pub-id pub-id-type="pmid">2473878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia and the role of the thalamus in sleep regulation.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2011</year>
            <volume>99</volume>
            <fpage>981</fpage>
            <page-range>981-96</page-range>
            <pub-id pub-id-type="pmid">21056239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hainfellner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;cke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jellinger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kleinert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Windl</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kretzschmar</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sidle</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Collinge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Budka</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia: a new Austrian family.</article-title>
            <source>Brain</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>122 ( Pt 1)</volume>
            <fpage>5</fpage>
            <page-range>5-16</page-range>
            <pub-id pub-id-type="pmid">10050890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krasnianski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bartl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanchez Juan</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Heinemann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Varges</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schulze-Sturm</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kretzschmar</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Schulz-Schaeffer</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Zerr</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia: Clinical features and early identification.</article-title>
            <source>Ann Neurol</source>
            <year>2008</year>
            <month>May</month>
            <volume>63</volume>
            <issue>5</issue>
            <fpage>658</fpage>
            <page-range>658-61</page-range>
            <pub-id pub-id-type="pmid">18360821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plazzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schutz</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Provini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Avoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heikkila</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tinuper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Solieri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Motor overactivity and loss of motor circadian rhythm in fatal familial insomnia: an actigraphic study.</article-title>
            <source>Sleep</source>
            <year>1997</year>
            <month>Sep</month>
            <volume>20</volume>
            <issue>9</issue>
            <fpage>739</fpage>
            <page-range>739-42</page-range>
            <pub-id pub-id-type="pmid">9406326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Medori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baruzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tinuper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zucconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei.</article-title>
            <source>N Engl J Med</source>
            <year>1986</year>
            <month>Oct</month>
            <day>16</day>
            <volume>315</volume>
            <issue>16</issue>
            <fpage>997</fpage>
            <page-range>997-1003</page-range>
            <pub-id pub-id-type="pmid">3762620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baldelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Provini</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia and Agrypnia Excitata: Autonomic dysfunctions and pathophysiological implications.</article-title>
            <source>Auton Neurosci</source>
            <year>2019</year>
            <month>May</month>
            <volume>218</volume>
            <fpage>68</fpage>
            <page-range>68-86</page-range>
            <pub-id pub-id-type="pmid">30890351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallassi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morreale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>"Fatal familial insomnia": neuropsychological study of a disease with thalamic degeneration.</article-title>
            <source>Cortex</source>
            <year>1992</year>
            <month>Jun</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>175</fpage>
            <page-range>175-87</page-range>
            <pub-id pub-id-type="pmid">1499304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calandra-Buonaura</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Capellari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tinuper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parchi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Gait disorders in fatal familial insomnia.</article-title>
            <source>Mov Disord</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>420</fpage>
            <page-range>420-4</page-range>
            <pub-id pub-id-type="pmid">24375448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallassi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morreale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Avoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Castellani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia: behavioral and cognitive features.</article-title>
            <source>Neurology</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>935</fpage>
            <page-range>935-9</page-range>
            <pub-id pub-id-type="pmid">8780067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia: sleep, neuroendocrine and vegetative alterations.</article-title>
            <source>Adv Neuroimmunol</source>
            <year>1995</year>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-21</page-range>
            <pub-id pub-id-type="pmid">7795890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ghorayeb</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rupprecht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reder</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Garay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Honda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nagayama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rosa-Neto</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gauthier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Proposal of new diagnostic criteria for fatal familial insomnia.</article-title>
            <source>J Neurol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>269</volume>
            <issue>9</issue>
            <fpage>4909</fpage>
            <page-range>4909-4919</page-range>
            <pub-id pub-id-type="pmid">35501502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Perani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gallassi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tinuper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Provini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Avoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferrillo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Anchisi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moresco</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Parchi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baruzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies.</article-title>
            <source>Brain</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>129</volume>
            <issue>Pt 3</issue>
            <fpage>668</fpage>
            <page-range>668-75</page-range>
            <pub-id pub-id-type="pmid">16399807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reder</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Mednick</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spire</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Van Cauter</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wollmann</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Cerven&#x000e0;kov&#x000e0;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Garay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ovsiew</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Clinical and genetic studies of fatal familial insomnia.</article-title>
            <source>Neurology</source>
            <year>1995</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>1068</fpage>
            <page-range>1068-75</page-range>
            <pub-id pub-id-type="pmid">7783865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zerr</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic trials in human transmissible spongiform encephalo-pathies: recent advances and problems to address.</article-title>
            <source>Infect Disord Drug Targets</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-9</page-range>
            <pub-id pub-id-type="pmid">19200019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forloni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tettamanti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lucca</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Albanese</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Quaglio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chiesa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Erbetta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Villani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Redaelli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tagliavini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Artuso</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roiter</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases.</article-title>
            <source>Prion</source>
            <year>2015</year>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>75</fpage>
            <page-range>75-9</page-range>
            <pub-id pub-id-type="pmid">25996399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burchell</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Panegyres</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Prion diseases: immunotargets and therapy.</article-title>
            <source>Immunotargets Ther</source>
            <year>2016</year>
            <volume>5</volume>
            <fpage>57</fpage>
            <page-range>57-68</page-range>
            <pub-id pub-id-type="pmid">27529062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Medori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tritschler</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>LeBlanc</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Villare</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manetto</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene.</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>Feb</month>
            <day>13</day>
            <volume>326</volume>
            <issue>7</issue>
            <fpage>444</fpage>
            <page-range>444-9</page-range>
            <pub-id pub-id-type="pmid">1346338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zerr</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kallenberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Summers</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taratuto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heinemann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Breithaupt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Varges</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ladogana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schuur</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Stokin</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Pimentel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hewer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Collie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brandel</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>van Duijn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pocchiari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Begue</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cras</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Will</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Sanchez-Juan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease.</article-title>
            <source>Brain</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>132</volume>
            <issue>Pt 10</issue>
            <fpage>2659</fpage>
            <page-range>2659-68</page-range>
            <pub-id pub-id-type="pmid">19773352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cracco</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Appleby</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia and sporadic fatal insomnia.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2018</year>
            <volume>153</volume>
            <fpage>271</fpage>
            <page-range>271-299</page-range>
            <pub-id pub-id-type="pmid">29887141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hainfellner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Brantner-Inthaler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cerven&#x000e1;kov&#x000e1;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kitamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tateishi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Diringer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liberski</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Regele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Feucht</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The original Gerstmann-Str&#x000e4;ussler-Scheinker family of Austria: divergent clinicopathological phenotypes but constant PrP genotype.</article-title>
            <source>Brain Pathol</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>201</fpage>
            <page-range>201-11</page-range>
            <pub-id pub-id-type="pmid">8520719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Jun</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>KY</given-names>
              </name>
            </person-group>
            <article-title>Fatal familial insomnia presenting with agrypnia excitata and very low atonia index level: A case report and literature review.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>May</month>
            <volume>97</volume>
            <issue>18</issue>
            <fpage>e0646</fpage>
            <pub-id pub-id-type="pmid">29718878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaudino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gangemi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Colantonio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Botto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruberto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Calandrelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vita</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Masullo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cerase</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colosimo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Neuroradiology of human prion diseases, diagnosis and differential diagnosis.</article-title>
            <source>Radiol Med</source>
            <year>2017</year>
            <month>May</month>
            <volume>122</volume>
            <issue>5</issue>
            <fpage>369</fpage>
            <page-range>369-385</page-range>
            <pub-id pub-id-type="pmid">28110369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kalakoti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Menger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guthikonda</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nanda</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy.</article-title>
            <source>Neurosurg Focus</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>E2</fpage>
            <pub-id pub-id-type="pmid">26646926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindsley</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Genetic and Rare Disease of the CNS. Part I: Fatal Familial Insomnia (FFI).</article-title>
            <source>ACS Chem Neurosci</source>
            <year>2017</year>
            <month>Dec</month>
            <day>20</day>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>2570</fpage>
            <page-range>2570-2572</page-range>
            <pub-id pub-id-type="pmid">29258312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parchi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Autilio-Gambetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Capellari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Monari</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Molecular pathology of fatal familial insomnia.</article-title>
            <source>Brain Pathol</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>539</fpage>
            <page-range>539-48</page-range>
            <pub-id pub-id-type="pmid">9669705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21637.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montagna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cortelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lugaresi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Familial and sporadic fatal insomnia.</article-title>
            <source>Lancet Neurol</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>167</fpage>
            <page-range>167-76</page-range>
            <pub-id pub-id-type="pmid">12849238</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
